Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-002 with Vismodegib in Locally Advanced Basal Cell Carcinoma
NCT06344052Phase 2Recruiting
- Sponsor
- Stamford Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- Sep 2026
- Modality
- Adenoviral Vectors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SP-002 in basal cell carcinoma (BCC) (3 arms), sponsored by Stamford Pharmaceuticals. Primary endpoint: Objective Response Rate at Week 26. Started Apr 2024; status: recruiting.
02
Drugs
SP-002
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT06344052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06344052.